Abstract
Blood is the most common source of biomarkers for use in the diagnosis and prognosis of malignant disease. Utilizing proteomic technology for biomarker identification offers greatly increased sensitivity. Such an increase in sensitivity requires precise sample preparation to eliminate any bias in analysis. Here, issues concerning the use of blood, plasma and serum for proteomic analysis are summarized.
Footnotes
- Received March 21, 2006.
- Revision received April 16, 2006.
- Accepted April 18, 2006.
- Copyright© 2006 International Institute of Anticaner Research (Dr. John G. Delinassios), All rights reserved